Andere Sprachen IntelGenx Technologies Corp. Toronto S.E.

Aktien

A0RP0X

US45822R1014

IGX

Schlusskurs Toronto S.E. Andere Börsenplätze 00:00:00 18.10.2021			% 5 Tage	% 1. Jan.
0,78 ^CAD	+9,86 %		+50,00 %	+173,68 %

08.04.	Intelgenx gibt bekannt, dass die ersten Parkinson-Patienten in der Phase 2-Studie "Montpark" mit Montelukast Versafilm® behandelt werden. Klinische Studie	CI
05.04.	IntelGenx aktualisiert Status von Buprenorphin Buccal Film ANDA	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial	08.04.
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	08.04.
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	08.04.
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05.04.
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05.04.
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	05.04.
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	21.03.
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results	21.03.
IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `	15.03.
IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `	15.03.
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow	14.03.
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	11.03.
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11.03.
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11.03.
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11.03.
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding	08.03.
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering	20.02.
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	20.02.
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding	14.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen IntelGenx Technologies Corp. Toronto S.E.

Aktien

A0RP0X

US45822R1014

IGX

Andere Sprachen

Filter